Rivaroxaban

Drug Profile

Rivaroxaban

Alternative Names: BAY-59-7939; JNJ-39039039; Xarelto

Latest Information Update: 07 Jul 2017

Price : $50

At a glance

  • Originator Bayer; Johnson & Johnson Pharmaceutical Research & Development
  • Developer Bayer; Janssen Research & Development; Johnson & Johnson; McMaster University; Population Health Research Institute
  • Class Amides; Anticoagulants; Antithrombotics; Morpholines; Oxazolidinones; Small molecules; Thiophenes
  • Mechanism of Action Factor IXa inhibitors; Factor Xa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Embolism; Stroke; Venous thromboembolism
  • Registered Acute coronary syndromes; Deep vein thrombosis; Pulmonary embolism
  • Phase III Atrial fibrillation; Cardiovascular disorders; Peripheral arterial disorders; Thromboembolism; Thrombosis
  • Phase II Coronary thrombosis

Most Recent Events

  • 12 Jul 2017 Mie University Graduate School of Medicine in collaboration with Bayer Yakuhin plans a clinical trial for Deep vein thrombosis in Japan (UMIN000028105)
  • 28 Jun 2017 FDA assigns PDUFA action date of 28/10/2017 for rivaroxaban for Venous thromboembolism (dose addition)
  • 28 Jun 2017 The US FDA accepts the sNDA for the 10 mg dose addition for the treatment of patients with Venous thromboembolism for Priority Review
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top